Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II IMRT with docetaxel, cisplatin and 5-FU for cervical esophageal squamous cell carcinoma (ISLAND-J)
jRCTs031210002Phase 2Recruiting
- Start
- Jan 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: 3-year overall survival. Started Jan 2022; status: recruiting.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCTs031210002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210002.